Skip to main content
Clinical Trials/NCT01092598
NCT01092598
Completed
Not Applicable

The Impact of Neurocognition and Symptomatology on Physical Function Among Older Adults With Schizophrenia

University of California, San Francisco1 site in 1 country46 target enrollmentMarch 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
University of California, San Francisco
Enrollment
46
Locations
1
Primary Endpoint
Physical Function
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Older adults with schizophrenia are a growing segment of the population yet their physical health status is poor. In order to design effective interventions, the contributing factors must be understood. Current data suggest the side effects of psychiatric medications, sociodemographic factors, and health care disparities are a few of the reasons for the poor physical health. There are only limited data on the impact of psychiatric symptomatology and neurocognition on the physical health of this population. These limited data indicate that worse symptomatology and poorer neurocognition may negatively impact physical functioning, a critical component to optimal physical health. The purpose of this pilot study is to begin to fill this knowledge gap by: 1. examining the relationship between neurocognitive function and physical function and 2. Examining the relationship between schizophrenia symptoms and physical function. 3. Examining the relationship between serum Brain Derived Neurotrophic Factor (BDNF) and physical function. Using a descriptive correlational design, 50 older adults (55+) with schizophrenia or schizoaffective disorder will be assessed. Bivariate associations will be used to examine the relationship between key variables including schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale (PANSS), neurocognitive function as measured with the MATRICS Consensus Cognitive Battery (MCCB), Physical Function as measured objectively by the Timed Get Up and Go (TGUG) test and subjectively with the physical component summary subscale of the 12-item short form health survey (SF-12), and serum BDNF. These pilot data will lay the foundation for a future health promoting intervention.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
May 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • English speaking adults older than or equal to 55 with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder that pass a capacity to consent test based on comprehension of the consent form.

Exclusion Criteria

  • Non-English speaking,
  • Adults younger than 55,
  • No diagnosis of schizophrenia of schizoaffective disorder, and/or
  • Not passing a capacity to consent test.

Outcomes

Primary Outcomes

Physical Function

Time Frame: enrollment

Study Sites (1)

Loading locations...

Similar Trials